Bayer AG

BAYN

DE000BAY0017

Pharmaceuticals

Real-time Estimate Tradegate Other stock markets 08:45:12 17/07/2024 pm IST			5-day change	1st Jan Change
26.66 ^EUR	+2.30%		+2.14%	-20.65%

05:07pm	Bayer: successful trial in prostate cancer	CF
01:51pm	BAYER AG : JP Morgan remains Neutral	ZD

BAYER AG : NorldLB reaffirms its Buy rating

January 14, 2021 at 07:21 pm IST

In a research note published by Thorsten Strauß, NorldLB advises its customers to buy the stock. The target price has been raised to EUR 61 from EUR 56.

Latest news about Bayer AG

Bayer: successful trial in prostate cancer	08:37pm	CF
BAYER AG : JP Morgan remains Neutral	05:21pm	ZD
Bayer: new positive data for Nubeqa	03:04pm	CF
Bayer with trial success in prostate cancer - Analyst: As expected	02:14pm	DP
BAYER AG : Goldman Sachs sticks Neutral	02:08pm	ZD
Bayer's Prostate Cancer Combo Extends Progression-Free Survival in Late-stage Trial	12:26pm	MT
Bayer's Nubeqa Meets Key Goal in Late-Stage Prostate Cancer Trial	11:38am	DJ
Bayer eyes wider Nubeqa use on new prostate cancer trial data	11:38am	RE
Bayer seeks approval extension for cancer drug Nubeqa following positive data	11:38am	RE
Bayer with trial success in prostate cancer - Larger patient group responsive	11:37am	DP
Orion Announces Phase III Aranote Trial of Darolutamide in Combination with Androgen Deprivation Therapy in Men with Metastatic Hormone-Sensitive Prostate Cancer Meets Primary Endpoint	11:00am	CI
ORIC Pharmaceuticals, Inc. Enters into Clinical Trial Collaboration and Supply Agreements with Bayer and Janssen Research & Development, LLC	17/07	CI
BAYER AG : UBS sticks Neutral	15/07	ZD
European companies cut jobs as economy sputters	15/07	RE
European Midday Briefing : Stocks Extend Rally as U.S. Rate Cut Hopes Deepen	12/07	DJ
BAYER AG : Jefferies gives a Neutral rating	12/07	ZD
Cooling Inflation in Germany, US Boosts DAX Index	11/07	MT
Bayer: FDA Fast Track designation for Parkinson's treatment	11/07	CF
Bayer's Gene Therapy for Parkinson's Gets US Fast Track, UK Innovation Passport Designations	11/07	MT
Fast-track status for gene therapy boosts Bayer	11/07	DP
BASF announces planned closure of two weed killer sites in Germany	10/07	RE
BAYER AG : JP Morgan reaffirms its Neutral rating	10/07	ZD
European companies cut jobs as economy sputters	09/07	RE
BAYER AG : Gets a Neutral rating from Deutsche Bank	09/07	ZD
That's not so bad, is it?	08/07

Bayer AG is one of the world's leaders in designing, producing, and marketing pharmaceutical products and agrochemicals. Net sales are distributed by product family as follows: - agrochemicals (48.8%): herbicides, fungicides, insecticides, etc.; - pharmaceutical products (38%): intended for the prevention and treatment of cardiovascular and respiratory diseases, diabetes, nervous system disorders, etc.; - OTC products and nutritional supplements (12.7%); - other (0.5%). Net sales are distributed geographically as follows: Germany (5.1%), Switzerland (1.2%), Europe-Middle East-Africa (23.2%), the United States (30.6%), North America (3.5%), China (7.6%), Asia-Pacific (10%), Brazil (10.4%) and Latin America (8.4%).

Sector

Pharmaceuticals

Calendar

06/08/2024 - Q2 2024 Earnings Release

Related indices

Euro STOXX 50 Index , STOXX EUROPE 600 (EUR) , DAX

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

BAYER : As soft as anticipated

May 14, 2024 at 11:42 pm IST

Bayer AG: Not out of the woods yet

March 06, 2024 at 09:16 pm IST

More Strategies

Ratings for Bayer AG

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

26.06 EUR

Average target price

35.91 EUR

Spread / Average Target

+37.82%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
BAYER AG	-20.65%	2.79TCr
ELI LILLY AND COMPANY	+56.91%	85TCr
NOVO NORDISK A/S	+31.59%	63TCr
JOHNSON & JOHNSON	-0.73%	36TCr
MERCK & CO., INC.	+15.00%	32TCr
ABBVIE INC.	+12.34%	30TCr
ASTRAZENECA PLC	+15.06%	24TCr
NOVARTIS AG	+16.70%	23TCr
AMGEN INC.	+15.89%	18TCr
PFIZER, INC.	+4.14%	17TCr

Other Pharmaceuticals

Bayer AG

Equities

BAYN

DE000BAY0017

Pharmaceuticals

BAYER AG : NorldLB reaffirms its Buy rating

Latest news about Bayer AG

Chart Bayer AG

Company Profile

Income Statement Evolution

Analysis / Opinion

Ratings for Bayer AG

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals